Lepu Medical Technology (Beijing) Co., Ltd.

Lepu Medical Technology (Beijing) Co., Ltd. is a manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2009. The company focuses on developing and supplying a comprehensive range of products and services related to cardiovascular health, including prevention, drug treatment, surgical intervention, and rehabilitation. Lepu aims to establish itself as a leading global player in the cardiovascular sector by integrating online and offline medical services across China. Lepu operates primarily in the medical device, pharmaceutical, and medical service sectors. It is known for its innovative products, such as bioabsorbable vascular stents and dual-chamber pacemakers, and is actively developing a range of cardiovascular drugs and diagnostic reagents. The company also emphasizes building a remote network platform for cardiovascular health services and aims to expand into new medical modes, including biopharmaceuticals and precision medicine. Through strategic partnerships and a focus on research and development, Lepu seeks to enhance its competitive position in the rapidly evolving healthcare market.

Lepu adheres to the innovation system of medical devices and drugs in accordance with the principle of "the generations of pre-research, registration, and production and sales". The major product, bioabsorbable vascular stent (NeoVas), which is researched and developed independently by our team, is a world revolution in the field of cardiovascular intervention. And following the registration of the homemade dual-chamber pacemaker, our GLP-1 exenatide and left atrial appendage occluder are going to be registered soon, which will fill the technology gap in China.In the next few years, there will be more than a dozen of major cardiovascular devices and medicine with the market capacity exceeding billions of dollars, which will further improve the cardiovascular drug platforms of research and development, supply and sales on anticoagulant, lipid-lowering, antihypertensive, heart failure, hypoglycemic and diabetic chronic diseases management, etc.Through Lepu's overall arrangement of cooperative hospitals in the major provinces, we aims at realizing the nationwide coverage of telemedicine services for the high-end medical resources of online hospital, and building cardiovascular health data platform and online & offline service network system centered on user-end. Orderly expand the fields of chronic diabetes management and new type cancer treatment, further develop new strategic businesses such as liquid biopsy and bio-innovative drugs, forming the core competitiveness of new technologies such as biopharmaceuticals, diabetes products and precision medicine to ensure a steady, high-speed and sustainable growth of the company, and to promote better returns for shareholders.